-USA, NY – Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointment of Gary Sender to its board of directors.
Mr. Sender will chair the Audit Committee and the Compensation Committee.
“We are proud to further bolster our board of directors with the appointment of Gary, a highly regarded leader in the life sciences industry who will serve as our Audit and Compensation Committee Chair,” said CEO and Board Chairman, Dr. Stephen Squinto, Ph.D.. “Gary’s business acumen and expertise in corporate financial management and build-out will be beneficial as we continue on a trajectory of rapid growth and development.”
About Gary Sender
Gary Sender is a seasoned executive and board member with more than 25 years of financial leadership experience in organizations ranging from large, multi-national pharmaceutical firms to early-stage biotechnology companies. He was CFO of Nabriva Therapeutics plc, a publicly-traded biopharmaceutical company, from 2016 until March 2021 when he retired. Before Nabriva, Mr. Sender served as CFO and executive vice president at Synergy Pharmaceuticals from 2015 to 2016, and as senior vice president, finance at Shire plc from 2009 until 2015, supporting its specialty pharmaceuticals business and subsequently its global commercial businesses. He was also the founding CFO of Tengion, Inc., and spent 15 years in several leadership roles within Merck.
“Gennao’s strong leadership team, broad-based technology platform, and commitment to transforming genetic medicine make this a very compelling opportunity,” said Garry Sender. “I look forward to assisting the Company to develop and fund a robust pipeline of GMAB therapeutics to benefit patients across several oncology and rare skeletal muscle diseases.”
Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie‑Mellon University.
About Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing, and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.
For more information: https://gennao.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
